FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study - Iwamoto, S; Takahashi, T; Tamagawa, H (Ann Oncol, 2015)